ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

ARGX vs RVMD // RETURN ON INVESTED CAPITAL (ROIC)

argenx SE (NASDAQ) VS. Revolution Medicines Inc. (NASDAQ) • 15-METRIC TALLY: ARGX 7 — RVMD 2
▲ RETURN ON INVESTED CAPITAL (ROIC) LEADER: ARGX
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ARGX VS. RVMD) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC ARGX RVMD SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) ACTIVE 9.90% -28.60% +38.50 ARGX /roic <GO>
EV/EBITDA & P/E Valuation 21.0x — — TIE /valuation <GO>
Free Cash Flow Yield 2.21% -2.24% +4.45 ARGX /fcf-yield <GO>
Operating Margin 13.90% — — TIE /operating-margins <GO>
Net Profit Margin 10.90% — — TIE /net-margins <GO>
Revenue Growth (YoY) 18.70% 15.40% +3.30 ARGX /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 3.74 26.00 -22.26 RVMD /balance-sheet <GO>
Piotroski F-Score Quality 8/9 5/9 +3.00 ARGX /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 51.7 47.8 +3.90 ARGX /rsi-technicals <GO>
10Y Yield & FRED Macro Beta 1.02 1.07 -0.05 RVMD /macro-sensitivity <GO>
Forward P/E Multiple 27.6x 34.0x -6.40 ARGX /forward-pe <GO>
Enterprise Scale & Market Cap $55.72B $40.78B $14.94B ARGX /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR ARGX REV RVMD REV ARGX GROSS % RVMD GROSS % ARGX FCF RVMD FCF
FY 2025 — $0 — — — -$913.7M
FY 2024 — $0 — — — -$567.7M
FY 2023 — $11.6M — — — -$351.1M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ARGX // BETA 1.02
RVMD // BETA 1.07